Medicus Pharma (NASDAQ:MDCX) Earns “Buy” Rating from D. Boral Capital

Medicus Pharma (NASDAQ:MDCX)‘s stock had its “buy” rating restated by D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They currently have a $27.00 price target on the stock.

MDCX has been the subject of a number of other research reports. Wall Street Zen raised Medicus Pharma from a “sell” rating to a “hold” rating in a report on Friday, May 30th. Maxim Group boosted their target price on Medicus Pharma from $10.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. Finally, D Boral Capital upgraded shares of Medicus Pharma to a “strong-buy” rating in a research note on Monday, April 14th. One research analyst has rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $23.50.

Medicus Pharma Price Performance

Medicus Pharma stock traded up $0.04 during mid-day trading on Monday, reaching $2.80. The stock had a trading volume of 60,862 shares, compared to its average volume of 128,624. Medicus Pharma has a one year low of $1.80 and a one year high of $8.94. The company’s 50-day moving average price is $4.43.

Medicus Pharma (NASDAQ:MDCX) last issued its earnings results on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.19). On average, equities analysts expect that Medicus Pharma will post -1.14 EPS for the current fiscal year.

Insider Activity

In other Medicus Pharma news, major shareholder Velocity Fund Partners, Lp sold 75,000 shares of Medicus Pharma stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $7.72, for a total transaction of $579,000.00. Following the transaction, the insider now owns 3,248,741 shares of the company’s stock, valued at $25,080,280.52. The trade was a 2.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Interchange Capital Partners LLC bought a new stake in Medicus Pharma in the 4th quarter valued at $3,628,000. Armistice Capital LLC purchased a new stake in shares of Medicus Pharma in the first quarter worth about $4,710,000. Finally, Private Advisor Group LLC bought a new position in Medicus Pharma during the first quarter valued at approximately $211,000.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.